STEER World Achieves Global Validation of Bioenergy and Pharmaceutical Technologies in 2025
In 2025, STEER World announced the successful global validation of its bioenergy and pharmaceutical technologies, supporting India's Compressed Biogas mission with plans for over 50 biogas plants by March 2026. The company also facilitated Bionpharma Inc.'s USFDA approval for generic Etravirine tablets using its FragMelt™ platform, while its Integraal™ Continuous Granulation System has been adopted for the commercial manufacture of seven drugs, underscoring India's advancements in deep-tech innovation across energy and healthcare sectors.
Theia Market Signal Identification - AI Assisted
In 2025, STEER World announced the commercial validation of its deep-tech platforms in bioenergy and life sciences. The company's technology supports India's Compressed Biogas (CBG) mission, with expectations to enable over 50 biogas plants by March 2026, producing over 1,000 tonnes of gas daily.
Additionally, STEERLife facilitated Bionpharma Inc.'s USFDA approval for generic Etravirine tablets, utilizing its FragMelt™ continuous processing platform to address formulation challenges. This achievement highlights India's role in advanced pharmaceutical manufacturing.
Furthermore, STEER World's Integraal™ Continuous Granulation System has been adopted for the commercial manufacture of seven drugs, promoting continuous manufacturing as a more efficient alternative to traditional processes. The developments signify a shift towards globally validated solutions in energy and healthcare sectors, positioning India as a leader in industrial deep-tech innovation.
Comments